Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02287467 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
A Phase 3 study of Influenza a and Influenza B, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 329
- Enrollment target
- 20
- Study locations
NCT02287467 is a Phase 3 study of Influenza a and Influenza B that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 329 participants, below the 2,721-participant average among 10 other Influenza a trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02287467, a Phase 3 study of Influenza a and Influenza B, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 329 participants
- Enrollment target
- 20
- Study locations
Study Summary
Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) in people who are hospitalized for severe flu.
Conditions Studied
Interventions
- BIOLOGICAL Intravenous hyperimmune immunoglobulin (IVIG)
- BIOLOGICAL Placebo for IVIG
Study Locations (20)
Ohio
- Case Western Reserve University - Cleveland
- OHIO State University (OSU) Wexner Medical Center - Columbus
- Miami Valley Hospital - Dayton
Other
- Westmead Hospital - Sydney
- Odense University Hospital - Odense
- St James's University Hospital - Leeds
Minnesota
- Minneapolis VA Medical Center - Minneapolis
- Mayo Clinic - Rochester
New York
- Cornell CRS - New York
- Montefiore Medical Center - The Bronx
California
- UCSD Antiviral Research Center (A VRC) - San Diego
Colorado
- Denver Public Health - Denver
Illinois
- University of Illinois - Chicago
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-06-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02287467
The ClinicalTrials.gov registry entry for NCT02287467 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,721-participant average among 10 other Influenza a trials with a reported enrollment target (88% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Influenza a appearing as the primary indexed condition, and to 2 interventions - of which Intravenous hyperimmune immunoglobulin (IVIG) is the first listed.
NCT02287467 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ohio, Other, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02287467 about?
NCT02287467 is a clinical study titled "Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza". Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) ...
What is the current status of trial NCT02287467?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 329 participants. The study started on 2015-01. Estimated completion is 2018-06-07.
What conditions does trial NCT02287467 study?
This clinical trial studies the following conditions: Influenza a, Influenza B.
What interventions are being tested in trial NCT02287467?
The interventions under investigation include: Intravenous hyperimmune immunoglobulin (IVIG) (BIOLOGICAL), Placebo for IVIG (BIOLOGICAL).
Who is sponsoring clinical trial NCT02287467?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02287467 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza a
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients
RECRUITING · NA
-
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
COMPLETED · Phase 1
-
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
COMPLETED
-
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
COMPLETED · Phase 1
-
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.